These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 3396362)

  • 1. A design for phase II testing of anticancer agents within a phase III clinical trial.
    Schaid DJ; Ingle JN; Wieand S; Ahmann DL
    Control Clin Trials; 1988 Jun; 9(2):107-18. PubMed ID: 3396362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase II clinical trials.
    Simon R; Wittes RE; Ellenberg SS
    Cancer Treat Rep; 1985 Dec; 69(12):1375-81. PubMed ID: 4075313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Design and analysis of phase II trials in oncology with a group sequential method, the triangular test].
    Bellissant E; Bénichou J; Chastang C
    Therapie; 1991; 46(1):21-7. PubMed ID: 2020920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statistical contributions to phase II trials in cancer: interpretation, analysis and design.
    Lee YJ; Wesley RA
    Semin Oncol; 1981 Dec; 8(4):403-16. PubMed ID: 7323812
    [No Abstract]   [Full Text] [Related]  

  • 5. The analysis of titration studies in phase III clinical trials.
    Shih WJ; Gould AL; Hwang IK
    Stat Med; 1989 May; 8(5):583-91. PubMed ID: 2727477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trial design in metastatic breast cancer: a commentary.
    Levine M
    Can J Oncol; 1995 Dec; 5 Suppl 1():40-2. PubMed ID: 8853523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methodology of antiemetic trials: response assessment, evaluation of new agents and definition of chemotherapy emetogenicity.
    Hesketh PJ; Gralla RJ; du Bois A; Tonato M
    Support Care Cancer; 1998 May; 6(3):221-7. PubMed ID: 9629873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trials in cancer: present status and analysis methods.
    Lee YJ
    Drugs Exp Clin Res; 1986; 12(1-3):57-71. PubMed ID: 3732056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II clinical trials.
    Carter SK; Selawry O
    Natl Cancer Inst Monogr; 1977 Mar; (45):81-92. PubMed ID: 337157
    [No Abstract]   [Full Text] [Related]  

  • 10. How large should a phase II trial of a new drug be?
    Simon R
    Cancer Treat Rep; 1987 Nov; 71(11):1079-85. PubMed ID: 3315196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
    Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
    Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review.
    Jardim DL; Groves ES; Breitfeld PP; Kurzrock R
    Cancer Treat Rev; 2017 Jan; 52():12-21. PubMed ID: 27883925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient designs for testing new agents and regimens.
    Ardizzoni A
    Chest; 1996 May; 109(5 Suppl):83S-86S. PubMed ID: 8635394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current issues in the design and interpretation of clinical trials.
    Pocock SJ
    Br Med J (Clin Res Ed); 1985 Jan; 290(6461):39-42. PubMed ID: 3917328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A tentative of guideline for phase III study and its problems in clinical aspect].
    Nakao I
    Gan To Kagaku Ryoho; 1984 Mar; 11(3):395-403. PubMed ID: 6703719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trials: use of a clinical tumor panel and overview of current resources and studies.
    Muggia FM; Rozencweig M; Chiuten DF; Jensen-Akula MS; Charles LM; Kubota TT; Bono VH
    Cancer Treat Rep; 1980 Jan; 64(1):1-9. PubMed ID: 6991100
    [No Abstract]   [Full Text] [Related]  

  • 18. Improving the design of phase II trials of cytostatic anticancer agents.
    Stone A; Wheeler C; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trials in cancer research.
    Gehan EA
    Environ Health Perspect; 1979 Oct; 32():31-48. PubMed ID: 232043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.